Emcure Pharmaceuticals (EMCURE) Panoramica del titolo
Emcure Pharmaceuticals Limited è impegnata nello sviluppo, nella produzione e nella commercializzazione di prodotti farmaceutici in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 5/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 2/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per EMCURE dai nostri controlli di rischio.
EMCURE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Emcure Pharmaceuticals Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹1,881.00 |
| Massimo di 52 settimane | ₹1,944.00 |
| Minimo di 52 settimane | ₹1,260.00 |
| Beta | -0.022 |
| Variazione di 1 mese | 0.042% |
| Variazione a 3 mesi | 14.84% |
| Variazione di 1 anno | 33.61% |
| Variazione a 3 anni | n/a |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 38.40% |
Notizie e aggiornamenti recenti
EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Recent updates
EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook
Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook
Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).EMCURE: Upcoming Governance And Roche Agreement Will Shape Balanced Forward Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals slightly higher to around ₹1,796 from about ₹1,795, citing updated assumptions for revenue growth, profit margins and a modestly lower future P/E expectation. What's in the News Emcure signed a distribution agreement with Roche for select nephrology and transplant medicines in India, covering therapies for chronic kidney disease, anemia management, and transplant care, effective April 1, 2026 (Key Developments).EMCURE: Upcoming Governance Decisions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margin and future P/E. This signals that their core view on the stock remains consistent.EMCURE: Weight Management Franchise Will Support Future Upside Potential
Analysts have kept their price target for Emcure Pharmaceuticals steady at ₹1,794.83, citing essentially unchanged assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Emcure plans a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.EMCURE: Weight Management Launch Will Underpin Future Shareholder Value Potential
Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794.83 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, which together support an unchanged price target narrative. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).EMCURE: Weight Management Launch Will Support Stronger Long Term Outlook
Analysts have nudged their price target on Emcure Pharmaceuticals higher from ₹1,688.50 to about ₹1,794.83, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E, which together support a slightly richer valuation framework. What's in the News Board meeting scheduled for Feb 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Here's Why We Think Emcure Pharmaceuticals (NSE:EMCURE) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...EMCURE: Weight Management Launch And Alliance Will Shape Balanced Outlook
Analysts have raised their fair value estimate for Emcure Pharmaceuticals from ₹1,652.50 to ₹1,688.50, reflecting updated assumptions related to revenue growth, profit margins and a slightly lower future P/E multiple. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Expansion In Chronic Therapies And Emerging Markets Will Thrive
Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report
The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark
Emcure Pharmaceuticals Limited's ( NSE:EMCURE ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
The Emcure Pharmaceuticals Limited ( NSE:EMCURE ) share price has fared very poorly over the last month, falling by a...We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Rendimenti per gli azionisti
| EMCURE | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 5.5% | -0.7% | -1.4% |
| 1Y | 33.6% | 10.2% | -0.2% |
Ritorno vs Industria: EMCURE ha superato il Indian Pharmaceuticals che ha restituito 10.2 % nell'ultimo anno.
Rendimento vs Mercato: EMCURE ha superato il mercato Indian che ha restituito -0.2 % nell'ultimo anno.
Volatilità dei prezzi
| EMCURE volatility | |
|---|---|
| EMCURE Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Prezzo delle azioni stabile: EMCURE non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di EMCURE è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1981 | 6,731 | Satish Mehta | www.emcure.com |
Emcure Pharmaceuticals Limited è impegnata nello sviluppo, nella produzione e nella commercializzazione di prodotti farmaceutici in tutto il mondo. Offre prodotti in varie aree terapeutiche, come ginecologia, cardiovascolare, antinfettivi, antivirali per l'HIV, respiratoria, gastrointestinale, antidolorifica e analgesica, ematologica, oncologica/antineoplastica, antidiabetica, ormonale, neurologica/sistema nervoso centrale, dermatologica e altre aree, nonché vitamine, minerali e nutrienti. L'azienda sviluppa inoltre prodotti su varie piattaforme, tra cui molecole chirali, API complessi, prodotti orali, prodotti a base di ferro, prodotti fotochimici, iniettabili liposomiali e liofilizzati, farmaci ad alta potenza, bioterapici e nuovi sistemi di rilascio dei farmaci.
Emcure Pharmaceuticals Limited Riepilogo dei fondamenti
| EMCURE statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹356.62b |
| Utili (TTM) | ₹9.24b |
| Ricavi(TTM) | ₹92.04b |
EMCURE è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EMCURE Conto economico (TTM) | |
|---|---|
| Ricavi | ₹92.04b |
| Costo del fatturato | ₹36.57b |
| Profitto lordo | ₹55.46b |
| Altre spese | ₹46.22b |
| Utili | ₹9.24b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 06, 2026
| Utile per azione (EPS) | 48.76 |
| Margine lordo | 60.26% |
| Margine di profitto netto | 10.04% |
| Rapporto debito/patrimonio netto | 24.2% |
Come si è comportato EMCURE nel lungo periodo?
Vedi performance storica e confrontoDividendi
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/26 21:23 |
| Prezzo dell'azione a fine giornata | 2026/07/24 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Emcure Pharmaceuticals Limited è coperta da 11 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | BOB Capital Markets Ltd. |
| Foram Parekh | BOB Capital Markets Ltd. |